SAN Sanofi

Sanofi : Information concerning the total number of voting rights and shares - July 2020

Sanofi : Information concerning the total number of voting rights and shares - July 2020

  

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,517,873,886 €

Registered office : 54, rue La Boétie – 75008 Paris – France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  



Total number of

issued shares



  		Number of real

voting rights

(excluding treasury shares) 		Theoretical number of

voting rights

(including treasury shares)*
July 31, 2020 1,258,936,943 1,411,160,146 1,413,755,067

*  Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

Europe Tel: 45           US Tel: 0

e-mail:



 



Media Relations Department

Tel: 46

 e-mail:



 

 

Attachment

EN
11/09/2020

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: New 48-week frexalimab phase 2 data support potential f...

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing se...

April 17, 2024 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : De nouveaux résultats de phase II à 48 semaines...

Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques Les données montrent que le frexalimab a le potentiel d’être le premier de sa classe pharmacothérapeutique pour le traitement de la sclérose en plaques récurrente-rémittente, en plus d’être hautement efficace et sans effet déplé...

April 17, 2024 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - March 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry un...

April 12, 2024 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 529 599 938 €Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris Date Nombre d’actions composant le capital  Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions auto-...

April 12, 2024 1 EN
Oliver Metzger
  • Oliver Metzger
ROG Roche Holding L...
OSE OSE Immunothera... ... (+14)

ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024

Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...

ROG ROCHE HOLDING LTD
OSE OSE IMMUNOTHERAPEUTICS SA
NOVN NOVARTIS AG
TFI TELEVISION FRANCAISE 1 SA
GXI GERRESHEIMER AG
FAGR FAGRON SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
SAN SANOFI
SLIGR SLIGRO FOOD GROUP N.V.
AZN ASTRAZENECA PLC
ALVGO VOGO SA
GSK GSK PLC
NOVO B NOVO NORDISK A/S
04/11/24 April 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch